From inflammation to cancer in inflammatory bowel disease: Molecular perspectives

Anticancer Research

Volumn 36, Issue 4, 2016, Pages 1447-1460

  Romano, Maurizio ^a   De Francesco, Francesco ^b   Zarantonello, Laura ^a   Ruffolo, Cesare ^c   Ferraro, Giuseppe A ^b   Zanus, Giacomo ^a   Giordano, Antonio ^d,e   Bassi, Nicolò ^c   Cillo, Umberto ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c TREVISO REGIONAL HOSPITAL   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e TEMPLE UNIVERSITY   (United States)

Author keywords

Chronic inflammation; Inflammatory bowel disease; Molecular biomarkers; New therapeutic concepts; Review; Tumor microenvironment

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ANTIINFLAMMATORY AGENT; BETA CATENIN; BEVACIZUMAB; BIOLOGICAL PRODUCT; CYCLOOXYGENASE 2; DNA METHYLTRANSFERASE 1; GLUCOCORTICOID; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 8; KRUPPEL LIKE FACTOR 6; MESALAZINE; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN P53; SALAZOSULFAPYRIDINE; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; STAT6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOCILIZUMAB; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; URSODEOXYCHOLIC ACID;

CANCER RISK; CANCER STEM CELL; CHRONIC INFLAMMATION; COLITIS; COLON CARCINOGENESIS; COLON POLYPOSIS; COLORECTAL CARCINOMA; CROHN DISEASE; DYSPLASIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INTESTINE CANCER; MICROSATELLITE INSTABILITY; MORBIDITY; MORTALITY; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; ANIMAL; COLORECTAL NEOPLASMS; COMPLICATION; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84984590561     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Castano-Milla C, Chaparro M and Gisbert JP: Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 39: 645-659, 2014.
2. Ullman TA and Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology 140: 1807-1816, 2011.
3. Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T and Sugihara K: Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 17: 802-808, 2011.
4. Boman BM and Wicha MS: Cancer stem cells: a step toward the cure. J Clin Oncol 26: 2795-2799, 2008.
5. Boman BM and Huang E: Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26: 2828-2838, 2008.
6. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C and Lin J: STAT3 is necessary for proliferation and survival in colon cancerinitiating cells. Cancer Res 71: 7226-7237, 2011.
7. Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J and Kudo M: Stress response protein CIRP links inflammation and tumorigenesis in colitis-associated cancer. Cancer Res 74: 6119-6128, 2014.
8. Shigdar S, Li Y, Bhattacharya S, O'Connor M, Pu C, Lin J, Wang T, Xiang D, Kong L, Wei MQ, Zhu Y, Zhou S and Duan W: Inflammation and cancer stem cells. Cancer Lett 345: 271-278, 2014
9. Romano M, De Francesco F, Pirozzi G, Gringeri E, Boetto R, Di Domenico M, Zavan B, Ferraro GA and Cillo U: Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience 2: 443-456, 2015.
10. Romano M, De Francesco F, Gringeri E, Giordano A, Ferraro GA, Di Domenico M and Cillo U: Tumor microenvironment versus cancer stem cells in cholangiocarcinoma: synergistic effects? J Cell Physiol 231: 768-776, 2016.
11. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M: IL6 and STAT3 are required for survival of intestinal epithelial cells and development of colitisassociated cancer. Cancer Cell 15: 103-113, 2009.
12. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M and Greten FR: GP130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitisassociated tumorigenesis. Cancer Cell 15: 91-102, 2009.
13. Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C and van der Woude CJ: IL6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 33: 1889-1896, 2012.
14. Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen WK, Vorvis C, Serebrennikova OB, Birli E, Choi J, Chang L, Anton PA, Tsichlis PN, Pothoulakis C, Verspaget HW and Iliopoulos D. MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology 149;981-992 2015.
15. Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, Ina K, Kanayama K, Ando T, Matsuura T, Yamaguchi T, Morise K, Ieda M, Iokawa H, Ishihara A and Sarai S. Elevation of interleukin-6 in inflammatory bowel disease is macrophage and epithelial cell-dependent. Dig Dis Sci 40: 949-959, 1995.
16. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S and GHores GJ: Sustained IL6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 132: 384-996, 2007.
17. Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ and van der Woude CJ: Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59: 227-235, 2010.
18. Li Y, de Haar C, Peppelenbosch MP and van der Woude CJ: New insights into the role of STAT3 in IBD. Inflamm Bowel Dis 18: 1177-1183, 2011.
19. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M andYao Y: Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 141: 125-139, 2014.
20. Rose-John S, Scheller J, Elson G and Jones SA: Interleukin-6 biology is coordinat-ed by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80: 227-236, 2006.
21. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S and Neurath MF: TGF-b suppresses tumor progression in colon cancer by inhibition of IL6 transsignaling. Immunity 21: 491-501, 2004.
22. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S and Takada T: Essential roles of IL6 trans-signaling in colonic epithelial cells, induced by the IL6/soluble-IL6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184: 1543-51, 2010.
23. Kado, S., K. Uchida, H. Funabashi, S. Iwata, Y. Nagata, M. Ando, M. Onoue, Y. Matsuoka, M. Ohwaki, and M. Morotomi. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor b chain and p53 double-knockout mice. Cancer Res 61: 2395-2398, 2001.
24. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF and Karin M: IKKa links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296, 2004.
25. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C and Mukaida N: Blocking TNFalpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560-570, 2008.
26. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK and DuBois RN: Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor a. Cancer Cell 6: 285-295, 2004.
27. Pai R, Nakamura T, Moon WS and Tarnawski AS: Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 17: 1640-1647, 2003.
28. Fan W, Maoqing W, Wangyang C, Fulan H, Dandan L, Jiaojiao R, Xinshu D, Binbin C and Yashuang Z. Relationship between the polymorphism of tumor necrosis factor-308 G>A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet 19: 432-437, 2011.
29. Abraham C and Cho J: Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 15: 1090-1100, 2009.
30. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD and Cua DJ. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 15: 1951-1957, 2003.
31. Duerr RH, Taylor KD, Brant SR,.Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL and Cho JH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-1463, 2006.
32. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ and Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910-1914, 2003.
33. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR and Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234, 2006.
34. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA and Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316, 2006.
35. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM and Sears CL: A human colonic commensal promotes colon tumorigenesis via activation of T-helper type 17 T-cell responses. Nat Med 15: 1016-1022, 2009.
36. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O and Bothwell AL: Ablation of IL17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 107: 5540-5544, 2010.
37. Hyun YS, Han DS, Lee AR, Eun CS, Youn J and Kim HY: Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 33: 931-936, 2012.
38. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D and Yu H: IL17 can promote tumor growth through an IL6-STAT3 signaling pathway. J. Exp Med 206: 1457-1464, 2009.
39. Hyun YS, Han DS, Lee AR, Eun CS, Youn J and Kim HY: Role of IL17A in the development of colitis-associated cancer. Carcinogenesis 33: 931-936, 2012.
40. Monteleone G, Pallone F and Macdonald TT: Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci 30: 441-447, 2009.
41. Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso R, Tersigni R, Alessandroni L, Biancone L, Naccari GC, MacDonald TT and Pallone F: Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128: 687-694, 2005.
42. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, Stolfi C, Cardolini I, Dottori M, Boirivant M, Pallone F, Macdonald TT and Monteleone G: Regulation of gut inflammation and TH17 cell response by interleukin-21. Gastroenterology 134: 1038-1048, 2008.
43. Stolfi C, Rizzo A, Franzè E, Rotondi A, Fantini MC, Sarra M, Caruso R, Monteleone I, Sileri P, Franceschilli L, Caprioli F, Ferrero S, MacDonald TT, Pallone F and Monteleone G: Involvement of interleukin-21 in the regulation of colitisassociated colon cancer. J Exp Med 208: 2279-2290, 2011.
44. Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, Caprioli F, Del Vecchio Blanco G, Paoluzi OA, Macdonald TT, Pallone F and Monteleone G: A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 132: 166-175, 2007.
45. Skak K., Kragh M, Hausman D, Smyth MJ and Sivakumar PV: Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 7: 231-240, 2008.
46. Wynn TA: IL13 effector functions. Annu Rev Immunol 21: 425-456, 2003.
47. Kelly-Welch A, Hanson EM and Keegan AD: Interleukin-13 (IL13) pathway. Sci STKE 293: cm8, 2005.
48. Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, Eppihimer MJ, Unger M, Tanaka T, Goldman SJ, Collins M, Donaldson DD and Grusby MJ: Enhanced interleukin (IL)-13 responses in mice lacking IL13 receptor alpha 2. J Exp Med 197: 703-709, 2003.
49. Mandal D and Levine AD: Elevated IL13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm Bowel Dis 16: 753-764, 2010.
50. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C and Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL5. J Immunol 157: 1261-1270, 1996.
51. Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T, Kinoshita K, Honjo T and Chiba T: Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 135: 889-898, 2008.
52. Endo Y, Marusawa H and Chiba T: Involvement of activationinduced cytidine deaminase in the development of colitisassociated colorectal cancers. J Gastroenterol 46: 6-10, 2011.
53. Takai A, Marusawa H, Minaki Y, Watanabe T, Nakase H, Kinoshita K, Tsujimoto G and Chiba T: Targeting activationinduced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene 31: 1733-1742, 2012.
54. Babyatsky MW, Rossiter G and Podolsky DK: Expression of transforming growth factor alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984, 1996.
55. Stadnicki A, Machnik G, Klimacka-Nawrot E, Wolanska-Karut A and Labuzek K: Transforming growth factor-beta1 and its receptors in patients with ulcerative colitis. Int Immunopharm 9: 761-766, 2009.
56. Wiercinska-Drapalo A, Flisiak R and Prokopowicz D: Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1. Cytokine 14: 343-346, 2001.
57. Ellenrieder V, Buck A and Gress TM: TGFbeta-regulated transcriptional mechanisms in cancer. Int J Gastrointest Cancer 31: 61-69, 2002.
58. Zavadil J and Bottinger EP: TGF-beta and epithelial-tomesenchymal transitions. Oncogene 24: 5764-5774, 2005.
59. Schäfer H, Struck B, Feldmann EM, Bergmann F, Grage-Griebenow E, Geismann C, Ehlers S, Altevogt P and Sebens S: TGF-1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells. Oncogene 32: 180-189, 2013.
60. Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P, Rose-John S, Neurath MF, Geissler EK, Schlitt HJ, Strober W and Fichtner-Feigl S: Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11bhighGr1low macrophages. J Clin Invest 121: 1692-1708, 2011.
61. Itzkowitz SH: Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 35: 553-571, 2006.
62. Chang CL, Marra G, Chauhan DP, Ha HT, Chang DK, Ricciardiello L, Randolph A, Carethers JM and Boland CR: Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 283: C148-154, 2002.
63. Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Koprowicz KM, Bronner MP and Brentnall TA: DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 162: 665-672, 2003.
64. Gerrits MM, Chen M, Theeuwes M, van Dekken H, Sikkema M, Steyerberg EW, Lingsma HF, Siersema PD, Xia B, Kusters JG, van der Woude CJ and Kuipers EJ: Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. Cell Oncol 34: 107-117, 2011.
65. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB and Issa JP: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59: 2307-2312, 1999.
66. Greenwald BD, Harpaz N, Yin J, Huang Y, Tong Y, Brown VL, McDaniel T, Newkirk C, Resau JH and Meltzer SJ: Loss of heterozygosity affecting the p53, Rb, and MCC/APC tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 52: 741-745, 1992.
67. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC and Burmer GC: Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107: 369-378, 1994.
68. Leedham SJ, Graham TA, Oukrif D, McDonald SA, Rodriguez-Justo M, Harrison RF, Shepherd NA, Novelli MR, Jankowski JA and Wright NA: Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 136: 542-550, 2009.
69. Lashner BA, Shapiro BD, Husain A and Goldblum JR: Evaluation of the usefulness of testing for p53 mutations in colorectal surveillance for ulcerative colitis. Am J Gastroenterol 94: 456-462, 1999.
70. Nathanson JW, Yadron NE, Farnan J, Kinnear S, Hart J and Rubin DT: p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci 53: 474-480, 2008.
71. Laurent C, Svrcek M, Flejou JF, Chenard MP, Duclos B, Freund JN and Reimund JM: Immunohistochemical expression of CDX2, catenin, and TP53 in inflammatory bowel diseaseassociated colorectal cancer. Inflamm Bowel Dis 17: 232-240, 2011.
72. Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Wilson KT, James SP, Herman JG and Meltzer SJ: Microsatellite instability in inflammatory bowel diseaseassociated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH11. Cancer Res 60: 4864-4868, 2000.
73. Bossard C, Denis MG, Bézieau S, Bach-Ngohou K, Bourreille A, Laboisse CL and Mosnier JF: Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. Oncol Rep 18: 1093-1097, 2007.
74. Aust DE, Haase M, Dobryden L, Markwarth A, Löhrs U, Wittekind C, Baretton GB and Tannapfel A: Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer 115: 673-677, 2005.
75. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A and DiNardo S: Arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 407: 527-530, 2000.
76. Clevers H and Nusse R: Wnt/catenin signaling and disease. Cell 149: 1192-1205, 2012.
77. Kuhl M, Sheldahl LC, Park M, Miller JR and Moon RT: The WNT/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 16: 279-283, 2000.
78. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, Koshida I, Suzuki K, Yamada G, Schwabe GC, Mundlos S, Shibuya H, Takada S and Minami Y: The receptor tyrosine kinase ROR2 is involved in non-canonical WNT5A/JNK signalling pathway. Genes Cells 8: 645-654, 2003.
79. Lien WH and Fuchs E: Wnt some lose some: transcriptional governance of stem cells by WNT/catenin signaling. Genes Dev 28: 1517-1532, 2014.
80. Koutroubakis IE, Tsiolakidou G, Karmiris K and Kouroumalis EA: Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 12: 515-523, 2006.
81. Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, Mocci G, Felice C, Ricci C, Andrisani G, Fedeli G, Gasbarrini G and Gasbarrini A: Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 26: 149-155, 2008.
82. Yoshimi K, Tanaka T, Serikawa T and Kuramoto T: Tumor suppressor APC protein is essential in mucosal repair from colonic inflammation through angiogenesis. Am J Pathol 182: 1263-1274, 2013.
83. Sugimura R and Li L: Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases. Birth Defects Res C Embryo Today 90: 243-256, 2010.
84. Vanuytsel T, Senger S, Fasano A and Shea-Donohue T: Major signaling pathways in intestinal stem cells. Biochim Biophys Acta 1830: 2410-2426, 2013.
85. Xing Y, Chen X, Cao Y, Huang J, Xie X and Wei Y: Expression of Wnt and Notch signaling pathways in inflammatory bowel disease treated with mesenchymal stem cell transplantation: evaluation in a rat model. Stem Cell Res Ther 6: 101, 2015.
86. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ and Tao Q: WNT5A exhibits tumor-suppressive activity through antagonizing the WNT/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 14: 55-61, 2008.
87. Reya T and Clevers H: WNT signalling in stem cells and cancer Nature 434: 843-850, 2005.
88. Shih IM, Wang TL, Traverso G, Romans K, Hamilton SR, Ben-Sasson S, Kinzler KW and Vogelstein B: Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 98: 2640-2645, 2001.
89. Dhir M, Montgomery EA, Glöckner SC, Schuebel KE, Hooker CM, Herman JG, Baylin SB, Gearhart SL and Ahuja N: Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg 12: 1745-1753, 2008.
90. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugaa I, Wasilewska A, Drews M, Majewski P, Karpiski T and Zwodziak B: Proinflammatory cytokines and IL10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp 57: 291-294, 2009.
91. Ben-Neriah Y and Karin M: Inflammation meets cancer, with NFappaB as the matchmaker. Nat Immunol 12: 715-723, 2011.
92. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ and Parkes M: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genet 42: 1118-1125, 2010.
93. McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD and Seielstad M: Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genet 42: 332-337, 2010.
94. Burkitt MD, Hanedi AF, Duckworth CA, Williams JM, Tang JM, O'Reilly LA, Putoczki TL, Gerondakis S, Dimaline R, Caamano JH and Pritchard DM: NF-B1, NF-B2 and c-Rel differentially regulate susceptibility to colitis-associated adenoma development in C57BL/6 mice. J Pathol 236: 326-336, 2015.
95. Zheng X, Tsuchiya K, Okamoto R, Iwasaki M, Kano Y, Sakamoto N, Nakamura T and Watanabe M: Suppression of HATH1 gene expression directly regulated by HES1 via NOTCh signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis 17: 2251-2260, 2011.
96. Tsuchiya K, Nakamura T, Okamoto R, Kanai T and Watanabe M: Reciprocal targeting of HATH1 and beta-catenin by WNT glycogen synthase kinase 3 beta in human colon cancer. Gastroenterology 132: 208-220, 2007.
97. Kano Y, Tsuchiya K, Zheng X, Horita N, Fukushima K, Hibiya S, Yamauchi Y, Nishimura T, Hinohara K, Gotoh N, Suzuki S, Okamoto R, Nakamura T and Watanabe M: The acquisition of malignant potential in colon cancer is regulated by the stabilization of Atonal homolog 1 protein. Biochem Biophys Res Commun 432: 175-181, 2013.
98. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ and Clevers H: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-U1, 2007.
99. Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Yamamoto H, Sekimoto M, Doki Y and Mori M: Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol 18: 1166-1174, 2011.
100. Fukushima K, Tsuchiya K, Kano Y, Horita N, Hibiya S, Hayashi R, Kitagaki K, Negi M, Itoh E, Akashi T, Eishi Y, Oshima S, Nagaishi T, Okamoto R, Nakamura T and Watanabe M: Atonal homolog 1 protein stabilized by tumor necrosis factor induces high malignant potential in colon cancer cell line. Cancer Sci 106: 1000-1007, 2015.
101. Kaptein A, Paillard V and Saunders M: Dominant negative Stat3 mutant inhibits interleukin-6-induced Jak-Stat signal transduction. J Biol Chem 271: 5961-5964, 1996.
102. Zhong Z, Wen Z and Darnell JE Jr.: STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.
103. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S and Neurath MF: IL6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4: 217-220, 2005.
104. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, MacSwords J, Cao Y, McLendon RE, Wang XF, Hjelmeland AB and Rich JN: Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404, 2009.
105. Lin L, Liu Y, Li H, Li PK, Fuchs J, Shibata H, Iwabuchi Y and Lin J: Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer 105: 212-220, 2011.
106. Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB, May R, Yang GY, Ragheb JW, Evers BM, Weber CR, Turner JR, He XC, Katzman RB, Li L and Barrett TA: Phosphoinositide 3-kinase signaling mediates catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139: 869-881, 2010.
107. Mao F, Xu M, Zuo X, Yu J, Xu W, Moussalli MJ, Elias E, Li HS, Watowich SS and Shureiqi I: 15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL6/STAT3 signaling pathway. FASEB J 29: 2359-2370, 2015.
108. Wang D and DuBois RN: PPAR? and PGE2 signaling pathways communicate and connect inflammation to colorectal cancer. Inflamm Cell Signal 1, 2014.
109. Connelly TM and Koltun WA: The cancer 'fear' in IBD patients: Is it still REAL? J Gastrointest Surg 18: 213-218, 2014.
110. Eaden J: Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2): 15-21, 2003.
111. Herfarth H: The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis. Dig Dis 30(Suppl 2): 55-59, 2012.
112. Foersch S and Neurath MF: Colitis-associated neoplasia: molecular basis and clinical translation. Cell Mol Life Sci 71: 3523-3535, 2014.
113. Kim YJ, Hong KS, Chung JW, Kim JH and Hahm KB: Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res 3: 1314-1333, 2010.
114. Baars JE, Looman CWN, Steyerberg EW, Beukers R, Tan AC, Weusten BL, Kuipers EJ and van der Woude CJ: The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nation-wide nested case-control study. Am J Gastroenterol 106: 319-328, 2011.
115. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I and Forbes A: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459, 2004.
116. Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, Chande N, Mosli M and Kim RB: Genetic predictors of azathioprine toxicity and clinical response in patients with inflammatory bowel disease. J Popul Ther Clin Pharmacol 23: e26-e36, 2016
117. Bvan Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD and Oldenburg B: Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 61: 235-240, 2012.
118. Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, Marti-Gallostra M, Spinelli A, van der Meulen-de Jong AE, Yuksel ES, Gasche C, Ardizzone S and Danese S: Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (I). J Crohns Colitis 8: 5-18, 2014.